Updates are available Correction dated 2025-09-08
Click to view Correction: https://doi.org/10.1007/s42000-025-00714-7
-
Authors
Kassi, Evanthia
Adamidou, Fotini
Yavropoulou, Maria P.
Anastasilakis, Athanasios D.
Makras, Polyzois
Vryonidou, Andromachi
Tournis, Symeon https://orcid.org/0000-0002-8301-324X
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 19 June 2025
First Online: 27 June 2025
Change Date: 8 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s42000-025-00714-7
Declarations
:
: EK reports fees for lectures/advisory boards from Amgen, AstraZeneca, Er-Kim, and UCB; FA reports fees for lectures/advisory boards from Amgen, Er-Kim, and Kyowa Kirin; MPY reports fees for lectures/advisory boards from Amgen, Er-Kim, Galenica, Genesis, and UCB; ADA reports fees for lectures/advisory boards from Amgen, Bianex, Eli-Lilly, Er-Kim, Galenica, ITF, Uni-pharma, and UCB; PM reports research grants from Amgen and Galenica and fees for lectures/advisory boards from UCB, Elpen, Bianex, and Eli-Lilly. AV reports fees for lectures/advisory boards from Er-Kim; and ST reports fees for lectures/advisory boards from Amgen, AstraZeneca, Elpen, Er-Kim, Genesis, and UCB;
